Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05509049
Other study ID # LRRHWWRCT
Secondary ID IRB 2129
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2022
Est. completion date January 9, 2024

Study information

Verified date January 2024
Source Lirio
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the present randomized controlled trial is to explore the effectiveness of a 12-month well woman digital health intervention leveraging Precision Nudging - the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time - in promoting behavior change. Specifically, it is hypothesized that scaling behavioral science through reinforcement learning will be more effective at motivating participants to engage with well woman messages and to schedule and to attend a well woman visit compared to a standard of care message.


Recruitment information / eligibility

Status Completed
Enrollment 30068
Est. completion date January 9, 2024
Est. primary completion date January 9, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Patient of health care system. - Visit with OBGYN office in the last 36 months. - OBGYN office provider is a Women's Wellness group approved provider. Exclusion Criteria: - Completed a women's wellness within the last 366 days. - Upcoming women's wellness appointment. - Had a childbirth episode (e.g., C-section vaginal delivery, or other event, including stillbirth) within the last 3 months or has a pregnancy due date in the future. - Unsubscribed.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Precision nudging
Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
Standard of care
Standard of care communication (e.g., personalized letters and patient portal notices)

Locations

Country Name City State
United States Rochester Regional Health New York New York

Sponsors (2)

Lead Sponsor Collaborator
Lirio Rochester Regional Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants who attended a well woman visit 3 months
Primary Proportion of participants who attended a well woman visit 6 months
Primary Proportion of participants who attended a well woman visit 9 months
Primary Proportion of participants who attended a well woman visit 12 months
Primary Proportion of participants who scheduled a well woman visit 3 months
Primary Proportion of participants who scheduled a well woman visit 6 months
Primary Proportion of participants who scheduled a well woman visit 9 months
Primary Proportion of participants who scheduled a well woman visit 12 months
Primary Proportion of participants who scheduled a well woman visit and did not attend (and did not Cancel and/or Reschedule) 3 months
Primary Proportion of participants who scheduled a well woman visit and did not attend (and did not Cancel and/or Reschedule) 6 months
Primary Proportion of participants who scheduled a well woman visit and did not attend (and did not Cancel and/or Reschedule) 9 months
Primary Proportion of participants who scheduled a well woman visit and did not attend (and did not Cancel and/or Reschedule) 12 months
Secondary Proportion of participants who opened and/or clicked Call-to-Action, or otherwise engaged with the communication(s) 3 months
Secondary Proportion of participants who opened and/or clicked Call-to-Action, or otherwise engaged with the communication(s) 6 months
Secondary Proportion of participants who opened and/or clicked Call-to-Action, or otherwise engaged with the communication(s) 9 months
Secondary Proportion of participants who opened and/or clicked Call-to-Action, or otherwise engaged with the communication(s) 12 months
See also
  Status Clinical Trial Phase
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Recruiting NCT04356924 - Psychological Treatment to Support the Consequences of Cognitive Impairment N/A
Completed NCT03904992 - Intervention With a Progressive Web App for the Promotion of Healthy Habits in Preschoolers N/A
Completed NCT05509270 - Efficacy of Communication Modalities for Promoting Flu Shots N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03081520 - Affective Responses Following Aerobic Exercise With Different Intensities N/A
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03982095 - Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
Completed NCT02777086 - Sustainable HIV Risk Reduction Strategies for Probationers N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Active, not recruiting NCT04152824 - Readiness Supportive Leadership Training N/A
Recruiting NCT05541653 - The IGNITE Study on Concentrated Investment in Black Neighborhoods N/A
Completed NCT03875768 - Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure N/A
Completed NCT04089020 - Walking to School Supports N/A
Completed NCT03646903 - Reducing Help-Seeking Stigma in Young Adults at Elevated Suicide Risk N/A
Completed NCT03548077 - POWERPLAY: Promoting Men's Health at Work N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Completed NCT06365450 - Breast and Cervical Cancer Education Program N/A
Completed NCT04323137 - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML N/A